Walid Kamoun, Vice President, Global Head of R&D Oncology at Servier, shared a post on LinkedIn:
“Super excited to announce a multi‑year collaboration between Servier and Insilico Medicine focused on discovering and developing novel oncology therapies.
By combining Servier’s oncology expertise with Insilico’s AI‑driven Pharma.AI platform, this partnership aims to accelerate drug discovery for some of the most challenging cancer targets and ultimately bring innovative and transformative medicines to patients faster.
A great example of how AI and strong partnerships can reshape pharmaceutical R&D.”
More posts featuring Walid Kamoun.